VYGR - Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)
2025-06-06 17:02:27 ET
Introduction
My last look at Voyager Therapeutics ( VYGR ) was September 2023. Voyager was developing a one-and-done Alzheimer’s gene therapy treatment. It was still seeking an IND, with a target in the first half of 2024. Moreover, partnerships with larger pharmaceutical companies, like Neurocrine Biosciences ( NBIX ), helped validate its technology. I recommended Buy, but with a “strong note of caution.”...
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)